Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rolinsatamab, an antibody targeting PRLR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Elipovimab, an antibody targeting HIV-1 gp120.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atoltivimab, an antibody targeting Zaire Ebolavirus Glycoprotein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vulinacimab, an antibody targeting VEGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Urabrelimab, an antibody targeting CD47.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tinurilimab, an antibody targeting CEACAM6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Simlukafusp, an antibody targeting FAP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Revdofilimab, an antibody targeting OX40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Petosemtamab, an antibody targeting EGFR × LGR5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Opucolimab, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nurulimab, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mirzotamab, an antibody targeting B7-H3.